Statin use and Pancreatic Cancer: A Meta-analysis of its Association with Incidence in the General Population and Survival in Patients
- Jibon Kumar Paul 1, Mahir Azmal 1, Omar Faruk Talukder 1, Ajit Ghosh 2
- 1Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh.
- 2Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh. aghosh-bmb@sust.edu.
- 0Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Statins may reduce pancreatic cancer risk and improve survival in patients with pancreatic ductal adenocarcinoma (PDAC). This meta-analysis suggests a potential benefit of statin use for pancreatic cancer outcomes.
Area Of Science
- Oncology
- Pharmacology
- Epidemiology
Background
- Statins are increasingly recognized for their potential anti-cancer properties.
- Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), has a poor prognosis.
- Understanding the role of common medications like statins in cancer management is crucial.
Purpose Of The Study
- To investigate the impact of statin use on pancreatic cancer incidence (morbidity).
- To evaluate whether statins improve survival rates (mortality) in patients diagnosed with PDAC.
- To synthesize evidence from multiple studies through a comprehensive meta-analysis.
Main Methods
- A systematic literature search was conducted up to July 2024 to identify eligible studies.
- Meta-analysis included 39 studies (case-control, cohort, RCTs) assessing statin use and PDAC.
- Random-effects models were used to calculate pooled risk ratios and confidence intervals; subgroup analyses were performed.
Main Results
- Overall meta-analysis showed a significant reduction in pancreatic cancer risk among all statin users (RR 0.94; p=0.0008).
- Long-term statin use was associated with reduced risk (RR 0.80; p=0.002) and improved survival (RR 0.81; p=0.007).
- No significant effect was observed for lipophilic statins or short-term use/follow-up; no publication bias was detected.
Conclusions
- The findings suggest that statins may play a role in lowering the incidence of pancreatic cancer.
- Statin therapy appears to be associated with improved survival outcomes for patients with PDAC.
- Further research may elucidate the specific mechanisms and optimal use of statins in pancreatic cancer care.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.